Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                Press Announcements

Press Announcements Home
          News & Events
          FDA Newsroom
          Press Announcements
          FDA launches mobile-friendly database with information on life-saving HIV drugs as part of ongoing mission to empower the public through increased access to information and dataPress Announcements FDA Statement
  FDA launches mobile-friendly database with information on life-saving HIV drugs as part of ongoing mission to empower the public through increased access to information and data

      Interactive tool offers information on ARVs eligible for purchase under the President’s Emergency Plan for AIDS Relief program
  
  Share
    Post
    Linkedin

    Email
    PrintFor Immediate Release:
                  January 29, 2020
                 
                         Statement From:
         Stephen M. Hahn, M.D.            Commissioner of Food and Drugs - Food and Drug Administration
  
                                  ( December 2019 - January 2021 )
 

 

  Français Português

Today, the U.S. Food and Drug Administration announced the launch of an interactive database that will offer a wealth of critical information about antiretrovirals (ARVs) eligible for purchase under the President’s Emergency Plan for AIDS Relief (PEPFAR) program. This launch is an important step in our ongoing commitment to address the global HIV epidemic and is consistent with our efforts to modernize and improve access to information and unleash the power of data.

In my years as a practicing physician, I spent time on-the-ground involved in a program for those impacted by HIV in Botswana, Africa. I saw first-hand how essential it is to have access to low-cost, life-saving treatments for those impacted by HIV, regardless of where a patient may reside. The PEPFAR program is designed to meet this critical need. It was created in 2003 to address the global HIV crisis in the hardest hit countries. PEPFAR was designed to bring together various federal government agencies that are involved in fighting the epidemic by creating a unified response, providing the most comprehensive, coordinated and targeted interventions. Since PEPFAR was launched 17 years ago, low-cost, quality-assured, life-saving ARVs have been provided to more than 15 million people worldwide, and PEPFAR remains the largest commitment by any nation to combat a single disease.

The FDA plays a critical role in the global fight against HIV by ensuring safe and effective ARVs are available worldwide, including those eligible for purchase through the PEPFAR program. The FDA’s role is to ensure that the safety, effectiveness and quality of HIV drugs distributed under PEPFAR is the same as for drugs used to treat HIV patients in the U.S. While the FDA ensures ARVs intended for the global market are held to the same high standard as PEPFAR drugs intended for the U.S. market, drugs intended for PEPFAR are sometimes issued tentative approval by the FDA. The only difference between FDA approval and tentative approval is that drugs that are tentatively approved cannot be sold inside the U.S. due to the existence of intellectual property protections in the U.S. such as patents. Tentative approval of ARVs has allowed for both new and generic versions of life-saving HIV treatments to be made available to the international community. Once a drug obtains approval or tentative approval the PEPFAR program can purchase ARVs at low cost and distribute them outside the U.S. to countries with high HIV burdens.

To implement the goals of PEPFAR, the FDA uses its existing processes, including expedited review to approve life-saving ARVs. To that end, the FDA has approved or tentatively approved 222 ARV applications for use in PEPFAR partner countries since 2004, of which 194 are still available for treatment today. Additionally, the FDA’s role of ensuring the availability of safe and effective HIV treatments reaches far beyond U.S.-based aid efforts, as global health entities, such as the Global Fund to Fight AIDS, Tuberculosis and Malaria and the World Health Organization (WHO), recognize FDA-approved ARVs as quality-assured drugs.

The list of the ARVs eligible for purchase in the PEPFAR program has long been publicly available on the agency’s website. By moving to an interactive, mobile-friendly database, we are empowering the public and health care providers by enhancing the amount and availability of information and data provided on each drug. For the first time, health care providers, consumers, and procurers will be able to easily access the FDA-reviewed product labeling, which will provide additional important information to patients and health care providers such as the full prescribing information (i.e., package insert) that contains a summary of essential scientific information needed for safe and effective use of the drug. In addition, there will be information on which drugs are suitable for pediatric populations, where each drug is manufactured, what its shelf-life is, and if the drug is subject to any storage requirements. Since the database platform is interactive, users will be able to export reports and collect metrics and can readily access this information on mobile platforms, which is important because in many PEPFAR partner countries this may be the only mode of receiving such information.

Given these numerous improvements, we anticipate that this database will be valuable to various public health stakeholders in the international HIV communities. The launch of this interactive database marks another step in the agency’s commitments to ensuring information regarding these life-saving ARVs are available to the public and is part of the agency’s continued dedication to fighting the HIV epidemic.

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

  Related Information
  
  Related Information
              www.fda.gov/PEPFAR
	Ending the HIV Epidemic: A Plan for America
	FDA’s Comprehensive Response to HIV — Part I
	FDA’s Comprehensive Response to HIV — Part II
	U.S. Department of State - PEPFAR

###
Inquiries
  
    
        
         Media:
                 
      
                            Kristen Pluchino
           
           
                      240-204-0861
    Consumer:
                        888-INFO-FDA

                                                                                  Content current as of:
      01/29/2020
               
               
Regulated Product(s)
		 Drugs   

        Follow FDA
            Follow @US_FDAon X
                Follow FDAon Facebook
                Follow @FDAMediaon XMore Press Announcements
 
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop